Humoral immune response in COVID-19 patients and novel design of lateral flow assay strip for simultaneous rapid detection of IgA/IgM/ IgG antibodies against the SARS-CoV-2 virus

Huong Thu Ngo Son Van Tran Hien Dang Nguyen Phong Quoc Truong   

Open Access   

Published:  Nov 10, 2022

DOI: 10.7324/JABB.2023.110209

At the end of 2019, a novel coronavirus (CoV) appeared in Wuhan, China and has since spread to several countries and regions throughout the world. The disease caused by the novel CoV has been officially named CoV disease 2019 (COVID-19). This study provides additional data for the presence of anti-SARS-CoV-2 IgM and IgG antibodies in COVID-19 patients in Vietnam. The study also presents the development of a lateral flow immunoassay (LFA) strip for rapid simultaneous detection of the IgA/IgM/IgG antibodies against the SARS-CoV-2 virus in COVID-19 patients. The properties of the LFA test strip were evaluated by testing specimens from COVID-19 positive and negative patients confirmed by real-time PCR. Reproducibility and repeatability reached 100%. The LFA test strip did not show any cross-reactivity with 13 different pathogens and did not interfere with anticoagulants. The sensitivity and specificity of the LFA test strips were evaluated with 633 clinical samples and were found to be 91.06% and 98.74%, respectively. The Kappa statistics showed almost perfect agreement and correlation between our test strip and real-time PCR results (k coefficient = 0.902). From the obtained results, it could be suggested that the LFA test strip is a useful tool for rapid detection of antibodies against SARS-CoV-2 to accelerate epidemiological surveillance, to determine the situation of exposure to SARS-CoV-2, and to increase the diagnostic accuracy of the real-time PCR method for COVID-19.

Keyword:     COVID-19 SARS-CoV-2 Antibody Lateral flow assay Humoral immune response Detection


Ngo HT, Tran SV, Nguyen HD, Truong PQ. Humoral immune response in COVID-19 patients and novel design of lateral flow assay strip for simultaneous rapid detection of IgA/IgM/IgG antibodies against the SARS-CoV-2 virus. J App Biol Biotech. 2022.

Copyright: Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

HTML Full Text

1. Biswas A, Bhattacharjee U, Chakrabarti AK, Tewari DN, Banu H, Dutta S. Emergence of novel coronavirus and COVID-19: Whether to stay or die out? Crit Rev Microbiol 2020;46:182-93.

2. Keni R, Alexander A, Nayak PG, Mudgal J, Nandakumar K. COVID-19: Emergence, spread, possible treatments, and global burden. Front Public Health 2020;8:216.

3. Guarner J. Three emerging coronaviruses in two decades. Am J Clin Pathol 2020;153:420-1.

4. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev 2020;7:CD013665.

5. Hanson KE, Caliendo AM, Arias CA, Englund JA, Lee MJ, Loeb M, et al. Infectious diseases society of America guidelines on the diagnosis of coronavirus disease 2019. Clin Infect Dis 2020:ciaa760.

6. Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, et al. Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea. Ann Lab Med 2020;40:351-60.

7. Russo A, Minichini C, Starace M, Astorri R, Calò F, Coppola N, et al. Current status of laboratory diagnosis for COVID-19: A narrative review. Infect Drug Resist 2020;13:2657-65.

8. Rahbaria R, Moradib N, Abdi M. rRT-PCR for SARS-CoV-2: Analytical considerations. Clin Chim Acta 2021;516:1-7.

9. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol 2020;17:773-5.

10. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes Infect 2020;9:940-8.

11. Hou H, Wang T, Zhang B, Luo Y, Mao L, Wang F, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology 2020;9:e1136.

12. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020;71:778-85. 13. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26:845-8.

14. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis 2020;71:2027-34.

15. Pieri M, Nuccetelli M, Nicolai E, Sarubbi S, Grelli S, Bernardini S. Clinical validation of a second generation anti-SARS-CoV-2 IgG and IgM automated chemiluminescent immunoassay. J Med Virol 2021;93:25238.

16. Nuccetelli M, Pieri M, Gisone F, Bernardini S. Combined anti-SARS-CoV-2 IgA, IgG, and IgM detection as a better strategy to prevent second infection spreading waves. Immunol Invest 2022;51:233-45.

17. Ching KH. Lateral flow immunoassay. Methods Mol Biol 2015;1318:127-37.

18. Zhang G, Guo J, Wang X. Immunochromatographic lateral flow strip tests. Methods Mol Biol 2009;504:169-83.

19. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-A resolution. Biochemistry 1981;20:2361-70.

20. Sasso EH, Silverman GJ, Mannik M. Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup. J Immunol 1991;147:1877-83.

21. Sambrook JF, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press; 2001.

22. Xia G, Wang J, Liu Z, Bai L, Ma L. Effect of sample volume on the sensitivity of lateral flow assays through computational modeling. Anal Biochem 2021;619:114130.

Article Metrics

2 Absract views 2 PDF Downloads 4 Total views

Related Search

By author names

Citiaion Alert By Google Scholar